Hucog Liquid Form 5000 (HCG 5000iu)

Product Overview

Hucog Liquid Form 5000 is a pharmaceutical preparation that contains Human Chorionic Gonadotropin (HCG) at a potency of 5000 International Units (IU) per vial. The product is manufactured by Bharat Serums and Vaccines Limited and is supplied in a sealed box that holds five individual vials. It is indicated for the treatment of female infertility and for the management of male hypogonadism, conditions in which stimulation of the reproductive hormones is required to support ovulation or testosterone production. The formulation is intended for use only under the supervision of a qualified healthcare professional.

What is Hucog Liquid Form 5000

Human Chorionic Gonadotropin is a glycoprotein hormone that is naturally produced by the placenta during pregnancy. In clinical practice, purified or recombinant HCG is administered to mimic the actions of luteinizing hormone (LH) and follicle‑stimulating hormone (FSH). The 5000 IU strength is frequently employed in assisted reproductive technologies, such as controlled ovarian stimulation, and in the treatment of hypogonadotropic hypogonadism in men. Because HCG shares structural similarity with LH, it can bind to the same receptors and trigger downstream signaling pathways that lead to sex‑steroid synthesis.

Uses and Benefits

In women, Hucog is used to induce ovulation in cycles of polycystic ovary syndrome (PCOS) or other ovulatory disorders, and it is also used to trigger final follicular maturation before oocyte retrieval in in‑vitro fertilization (IVF) protocols. In men, the medication stimulates Leydig cells in the testes to produce testosterone, thereby alleviating symptoms associated with primary or secondary hypogonadism, such as low libido, fatigue, and reduced muscle mass. The therapeutic benefit derives from its ability to provide a potent, short‑acting hormonal signal that can be titrated to achieve the desired physiological response while minimizing the duration of exposure.

How It Works

After reconstitution, HCG binds to the LH/hCG receptors located on ovarian granulosa cells and on Leydig cells in the testes. This binding activates intracellular cyclic adenosine monophosphate (cAMP) pathways that increase the expression of steroidogenic enzymes. In the ovary, the resulting rise in intracellular cAMP promotes follicular growth and final maturation, culminating in ovulation when timed appropriately. In the testes, the same cascade stimulates cholesterol conversion to testosterone, which can restore normal androgen levels and improve clinical symptoms.

Dosage Guidelines

Dosage of Hucog Liquid Form 5000 must be individualized by a physician based on the patient’s weight, baseline hormone levels, and treatment goals. Common clinical regimens include:

• For ovulation induction in women, a single dose of 5000 IU is typically administered after ultrasound documentation of a mature follicle, followed by timed intercourse or oocyte collection.
• In assisted reproduction cycles, multiple doses may be given over several days to maintain adequate hormone levels and to support luteal phase support.
• For male hypogonadism, a typical schedule involves an intramuscular injection of 5000 IU once weekly, with dose adjustments guided by serum testosterone measurements and clinical response.

Patients should never self‑administer without medical supervision, and baseline laboratory tests should be repeated at regular intervals to ensure that hormone levels remain within the therapeutic window.

Side Effects

Like all hormonal medications, Hucog can produce side effects. The most frequently reported adverse events are mild and include irritation at the injection site, headache, and transient abdominal discomfort. More serious but less common complications may include:

• Ovarian hyperstimulation syndrome (OHSS) in women, characterized by abdominal distension, nausea, rapid weight gain, and potentially ascites.
• Allergic reactions ranging from simple skin rash to severe anaphylaxis.
• Breast tenderness or enlargement, especially in women.
• Acne, mood swings, or mild fluid retention.

If any of these symptoms become severe or persist beyond a few days, patients should contact their healthcare provider immediately.

Warnings and Precautions

Before initiating therapy with Hucog, a thorough medical evaluation is essential. Important precautions include:

• Confirming that the patient is not pregnant, as HCG administration during an established pregnancy can be harmful.
• Screening for underlying conditions that predispose to thromboembolic events, such as a history of deep‑vein thrombosis.
• Adjusting dosage in patients with impaired renal or hepatic function, as these organs are involved in hormone clearance.
• Avoiding use in individuals with a known hypersensitivity to HCG or any of the excipients present in the formulation.

Pregnant or breastfeeding women should not receive Hucog unless a physician explicitly determines that the benefits outweigh the risks.

Frequently Asked Questions

Question: Can Hucog be used for weight loss?
Answer: No. Hucog is indicated solely for the treatment of infertility and hypogonadism; it is not approved for weight management and should only be used as prescribed for its approved indications.

Question: How is Hucog administered?
Answer: The medication is supplied as a lyophilized powder that must be reconstituted with sterile water before injection. It is typically administered intramuscularly or subcutaneously under medical supervision.

Question: Is Hucog safe for patients with polycystic ovary syndrome (PCOS)?
Answer: Yes, when used according to a physician’s protocol. However, women with PCOS have an increased risk of ovarian hyperstimulation syndrome, so close monitoring is essential.

Question: What is the storage requirement for Hucog?
Answer: Unopened vials should be stored in a refrigerator maintained at 2 to 8 °C. Once reconstituted, the solution can be kept at room temperature for up to 24 hours before use.

Question: Are there any drug interactions with Hucog?
Answer: Hucog has few clinically significant drug interactions, but it may potentiate the effects of other gonadotropins or hormonal therapies. Patients should inform their healthcare provider of all medications and supplements they are taking.

For additional details regarding indications, contraindications, and safety information, refer to the official prescribing information or consult a qualified healthcare professional.

Further scientific context can be found in peer‑reviewed resources such as the National Institutes of Health, the Drugs.com monograph, and the MedlinePlus database.

Related Products

• Enoxaparin 300 mg Injection (Generic)
• Enoxaparin 60mg Injection (Generic)
• Lonopin Pen (Only Pen) (Device)
• Lonopin 60mg Injection (Enoxaparin)
• Enoxaparin 40mg Injection (Generic)
• Lonopin 40mg Injection (Enoxaparin)
• Enoxaparin 20mg Injection (Generic)
• Lonopin 20mg Injection (Enoxaparin)
• Lonopin MD 300 mg Injection (Enoxaparin)
• Ovidac (HCG (HUMAN CHORIONIC GONADOTROPIN))
• hCG 10000iu Injection (Human Chorionic Gonadotropin)
• hCG 5000iu Injection (Human Chorionic Gonadotropin)